Flocked Swab 생산 전문 제조업체 & CHG 제품.

견적

» 회사 뉴스 » What obstacles should be cleared before the full vaccination in COVID-19

COVID-19에서 전체 예방 접종 전에 어떤 장애물을 제거해야합니까?

2020-12-04

전 세계 의료계는 전례 없는 속도와 규모로 코로나19 백신을 개발하고 있다., 그리고 각국 정부는 백신이 출시되어 실용화되는 것에 대해 큰 기대를 갖고 있습니다.. 최근에, 전 세계에서 개발 중인 여러 백신이 자주 보고되고 있습니다.. 지난 달, 여러 유명 백신이 3상 임상시험의 유효성을 발표했습니다.; 12월에 2, the British government approved the use of COVID-19 vaccine developed by Pfizer and German biotechnology companies; Mardner also announced that it will test COVID-19 vaccine on children … Despite this, Nature pointed out in the report that this does not mean that the vaccine will be fully vaccinated soon. Before that, solving the problems of vaccine hesitation, supply logistics, distribution, pricing and payment will help clear the obstacles.

Pfizer Pharmaceuticals Co., 주식회사. announced on November 9 that the COVID-19 vaccine developed by Pfizer in cooperation with German Biotechnology Company was more than 90% effective in Phase III clinical trials. The Independent reported on November 26th that American pharmaceutical company Mardner announced that the candidate COVID-19 vaccine developed by them was more than 90% 효과적인. 게다가, Oxford University and AstraZeneca Company also claimed that the average curative effect of a candidate COVID-19 vaccine developed by them was 70.4%. Early studies have shown that these candidate vaccines can stimulate the immune response. The latest experiment proves that this immune response can protect people from COVID-19.

On December 2nd, the British government announced that its Medicines and Health Products Administration (MHRA) had approved the use of COVID-19 vaccine developed by Pfizer and German biotechnology companies, which will be launched in Britain from next week. This urgent authorization cleared the way for vaccine deployment in Britain! On November 30th, 현지 시각, American Mardner Company applied to the US Food and Drug Administration (FDA) for emergency use of its candidate vaccine, saying that its vaccine was effective and there was no “serious safety problem” during the trial. According to a report in the Capitol Hill Daily on the 2nd, Mardner Company said that it would recruit 3,000 teenagers aged 12-17 to test COVID-19 vaccine to evaluate the safety of single dose vaccine, and the results are expected to be announced in 2022.